By Stephen NakrosisShares of biopharmaceutical company Puma Biotechnology Inc. are higher in Tuesday's late-trading session, after the company said the U.S. Patent and Trademark Office extended the patent claim for Nerlynx by five years. The patent will now expire on Dec. 29, 2030, the company said.
Source: Wall Street Journal November 23, 2021 23:50 UTC